SCHEMBL20249389

SCHEMBL20249389

CC(C)(C)c1ccc(N2CCN(CC(N)=O)CC2)nn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
TRPV1 Q8NER1 1/20 0.40
PARP1 P09874 1/20 0.40
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
GAA P10253 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
KMT2A Q03164 1/20 0.38
GPR119 Q8TDV5 1/20 0.38
AOC3 Q16853 2/20 0.37
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA7 P43166 2/20 0.36
CA12 O43570 1/20 0.36
HTR4 Q13639 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20255338 0.84 ALDH1A1 (0.42) ALDH1A1TRPV1GAAMEN1KMT2A
SCHEMBL20249420 0.84 TRPV1 (0.39) ALDH1A1TRPV1GPR119
SCHEMBL20249398 0.83 GFER (0.49) ALDH1A1TRPV1MEN1KMT2A
SCHEMBL20255391 0.82 AOC3 (0.42) ALDH1A1PARP1HSP90AA1HSP90AB1CYP1A2
SCHEMBL20249352 0.81 TRPV1 (0.39) TRPV1CYP1A2GAAGPR119VEGFA
SCHEMBL20255336 0.81 ALDH1A1 (0.51) ALDH1A1MEN1KMT2A
SCHEMBL20249404 0.80 NPC1 (0.54) ALDH1A1CYP1A2GAAMEN1POLB
SCHEMBL20249371 0.80 HTR1A (0.41) ALDH1A1TRPV1GAAGPR119
SCHEMBL20249151 0.79 GAA (0.47) ALDH1A1TRPV1CYP3A4GAACYP2C9
SCHEMBL20249351 0.79 TRPV1 (0.38) TRPV1GAAGPR119VEGFAEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TEIJIN PHARMA LIMITED (JP) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180161329-A1 PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF CDK4, CDK6, CDK16 ALDH1A1 944/4885TRPV1 3672/4885PARP1 819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.